ADAMTS13, recombinant-krhn 500 UNT Injection

RxCUI: 2670311
RxNorm name: ADAMTS13, recombinant-krhn 500 UNT Injection
Display name: ADAMTS13, recombinant-krhn 500 UNT Injection
Full name: ADAMTS13, recombinant-krhn 500 UNT Injection
Term type: SCD
Status: DailyMed mapping
Updated: 2026-06-04 23:38:50

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
125795	ADZYNMA	ADAMTS13, recombinant-krhn	351(a)	Rx	2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
ADZYNMA	APADAMTASE ALFA	TAKEDA PHARMACEUTICALS AMERICA, INC.	22728e96-efa0-46c1-bdd1-ad89a796d5e3	2026-08-20	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2670311

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
22728e96-efa0-46c1-bdd1-ad89a796d5e3	ADAMTS13, recombinant-krhn 500 UNT Injection [PSN] · ADAMTS13, recombinant-krhn 500 UNT Injection [SCD]	2	6	These highlights do not include all the information needed to use ADZYNMA safely and effectively. See full prescribing information for ADZYNMA. ADZYNMA (ADAMTS13, recombinant-krhn) lyophilized powder for Injection, for intravenous use Initial U.S. Approval: 2023	20240830